Progyny, Inc. has reported record financial results for the third quarter of 2026, highlighting significant growth across key metrics. The company’s performance reflects strong demand for its services in women's health and family building solutions. This announcement comes at a time when the healthcare industry is facing rising costs, making Progyny's achievements particularly noteworthy.

On November 4, 2026, Progyny disclosed its financial results for the fiscal quarter ended September 30, 2026. The company reported a revenue of $341.3 million, up from $313.3 million in the same period last year. Gross profit also saw a substantial increase, reaching $83.7 million compared to $72.8 million in Q3 2025. This growth is attributed to a successful selling season, which yielded 1.3 million new covered lives and nearly 100% retention of existing clients.

Progyny, Inc. is categorized under the SIC code 8090, which encompasses services in miscellaneous health and allied services. The company trades on the Nasdaq under the ticker PGNY and is recognized as a leader in women's health solutions. Its recent filing with the SEC, accession number 0001551306-26-000163, details these impressive results and outlines the company's ongoing commitment to delivering value to its clients.

The filing indicates that Progyny’s Chief Executive Officer, Pete Anevski, expressed satisfaction with the results, stating, "We’re exceptionally pleased with the results of our most recent selling season, where our momentum extended even into its latest stages, yielding 1.3 million new covered lives, our most ever in a single season, and over 85 new clients." He emphasized the importance of the services provided, especially in light of the pressures employers face from rising medical costs.

Mark Livingston, the Chief Financial Officer, also commented on the company’s performance, noting, "We achieved strong top- and bottom-line growth this quarter, reflecting that member engagement was consistent with our expectations." He highlighted the company's ability to convert Adjusted EBITDA to operating cash flow, providing flexibility for continued investment and shareholder returns.

In addition to the impressive revenue and profit figures, Progyny has raised the midpoint of its full-year guidance, indicating confidence in sustaining this growth trajectory into 2027. The company’s ability to maintain high retention rates and attract new clients positions it well within the competitive landscape of health services.

Looking ahead, Progyny's management is optimistic about extending its momentum into the next year. The company is set to leverage its strong pipeline of opportunities to continue delivering value and innovative solutions in the health services sector.

As the health services industry evolves, Progyny's results may influence competitors to reassess their strategies to remain competitive. The company's focus on comprehensive coverage and innovative solutions in women's health could set a benchmark for others in the sector.

Details were not available in the SEC filing regarding specific next steps following this announcement. However, the strong financial performance and strategic outlook suggest that Progyny is well-prepared to navigate the challenges and opportunities that lie ahead in the health services market.